TKM.TO Stock UPDATES Tekmira Pharmaceuticals Corporation (TKM.TO)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tekmira Pharmaceuticals Corporation (TKM.TO) 23.00 $TKM.TO

Nasdaq stocks posting largest volume increases
AP - Fri Aug 08, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:

Nasdaq stocks posting largest percentage increases
AP - Fri Aug 08, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Most active Nasdaq-traded stocks
AP - Fri Aug 08, 5:06PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:

Gap and Post Holdings are big market movers
AP - Fri Aug 08, 3:36PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:

IIROC Trade Resumption - TKM
CNW Group - Fri Aug 08, 7:13AM CDT
Trading resumes in:

Tekmira Conference Call and Webcast Advisory: Corporate Update and Second Quarter Financial Results
GlobeNewswire - Thu Aug 07, 7:36PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it will hold a conference call and webcast on Wednesday, August 13, 2014 at 2 p.m. Pacific Time (5 p.m. Eastern Time) to provide a corporate update and report financial results for the second quarter ended June 30, 2014.

FDA lifts hold on experimental Ebola drug
By MATTHEW PERRONE - AP - Thu Aug 07, 6:26PM CDT
WASHINGTON (AP) — U.S. health authorities have eased safety restrictions on an experimental drug to treat Ebola, a move that could clear the way for its use in patients infected with the deadly virus.

FDA Modifies Tekmira's TKM-Ebola Clinical Hold to Partial Hold
GlobeNewswire - Thu Aug 07, 3:45PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that the U.S. Food & Drug Administration (FDA) has verbally confirmed they have modified the full clinical hold placed on the TKM-Ebola Investigational New Drug Application (IND) to a partial clinical hold. This action enables the potential use of TKM-Ebola in individuals infected with Ebola virus.

IIROC Trading Halt - TKM
CNW Group - Thu Aug 07, 3:21PM CDT
The following issues have been halted by IIROC:

Tekmira Provides Update on TKM-Ebola Phase I Clinical Hold
GlobeNewswire - Mon Jul 21, 11:19AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced an update on the TKM-Ebola Phase I clinical hold. The Company has received the clinical hold letter from the U.S. Food and Drug Administration (FDA) and is preparing a Complete Response to the Agency. The Company anticipates this matter will be resolved by Q4, 2014.

Tekmira Receives $1.5 Million Milestone Payment
GlobeNewswire - Wed Jul 09, 6:00PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has received a $1.5 million milestone payment from Monsanto following completion of specified program developments. The development milestone is part of the research program under the Option Agreement Tekmira signed with the agriculture company, which we announced on January 13, 2014. The Option Agreement relates to Tekmira's proprietary delivery technology and intellectual property for use in agricultural applications. The potential value of the transaction could reach up to $86.2 million, following the successful completion of all program milestones.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 62

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 299

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 343

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 29

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 123

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 456

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading

Top 5 Most Recently Viewed Articles

Brazil Potash Secures $75 Million Equity Line for Growth

Updated Category News Views 167

Brazil Potash Secures Key Funding for Autazes Project Brazil Potash Corp. (“Brazil Potash” or the “Company”) (NYSE American: GRO), a prominent player in mineral development focused on potash mining, has recently finalized a significant agreement establishing an equity line of credit (ELOC) with Alumni Capital LP. This collaboration signals a crucial step in...

Continue Reading
AGCO Completes Major Strategic Shift Transforming Business Focus

Updated Category News Views 101

AGCO Completes Divestiture of Grain & Protein Business AGCO Corporation (NYSE: AGCO), a leading firm in agricultural machinery and precision ag technology, has finalized the sale of the majority of its Grain & Protein business to American Industrial Partners (AIP) in an all-cash deal valued at around $700 million. This significant transition emphasizes AGCO's focus on...

Continue Reading
Vincent Bouatou Takes the Helm as CTO at IDEMIA Public Security

Updated Category News Views 64

Vincent Bouatou Appointed as Chief Technology Officer With a wealth of experience in the technology sector, Vincent Bouatou has been officially announced as the Chief Technology Officer (CTO) of IDEMIA Public Security. His extensive background in driving technological innovations positions him to make significant strides in the biometric technology industry. Driving...

Continue Reading
MedX Holdings, Inc. Reaches New Heights in Q1 Revenue Growth

Updated Category News Views 171

MedX Holdings, Inc. Reports Extraordinary Q1 Revenue Gains MedX Holdings, Inc. (OTC: MEDH) is delighted to share its impressive financial results for the first quarter of 2025. With record revenue levels and strategic advancements, this milestone reflects the company's commitment to becoming a prominent player in cannabis retail, technology, and franchise development....

Continue Reading
Erste Group Upgrades WW Grainger Stock Amid Positive Outlook

Updated Category News Views 74

Erste Group upgraded WW Grainger (NYSE: GWW) from Hold to Buy back in mid-2024, showing that the desks had a new favorite. With a return on equity at a whopping 59%, Grainger's performance left many competitors in the dust, making it a must-watch stock for anyone looking to get into industrial supply chains. What's Driving the Upgrade? The reasons behind this rating shift...

Continue Reading